Good Pharma Scorecard
We rank bio-pharmaceutical companies and new drugs on ethics and public health performance criteria, focusing on issues that are critical to patients.
We rank bio-pharmaceutical companies and new drugs on ethics and public health performance criteria, focusing on issues that are critical to patients.
The Good Pharma Scorecard ranks companies and new medicines on their clinical trial transparency and data-sharing performance, taking into account ethics and legal standards. Subsequent versions of the scorecard will also evaluate the integrity of clinical trial designs, the accessibility of medicines, drug marketing practices, and other ethics and human rights issues.
Transparency is key to protecting and respecting research participants and users of medicines and vaccines
Evidenced based medicine requires all evidence to be in the public domain
Being able to learn from what other scientists have already done- both accomplishments and failures- stimulates innovation and ultimately the delivery of lifesaving results.
Transparency is key to maximizing the value of generated trial data and people’s participation in trials
Opacity can drive up costs of research and care
Transparency and data-sharing enable validation and replication of study findings
Sanofi / Genzyme
Merck
Median: 91%
Roche / Genentech
Novartis
Gilead
Company ranking
higher than last year
Company ranking
lower than last year
Company ranking
unchanged from last year